Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety and efficacy of a single injection of CNTX-4975 in subjects with chronic, moderate to severe osteoarthritis knee pain.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Subjects will receive a single injection of placebo into the index knee following local anesthesia and adjunct joint cooling. |
|
| 0.5 mg CNTX-4975 | Experimental | Subjects will receive a single injection of 0.5 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling. |
|
| 1.0 mg CNTX-4975 | Experimental | Subjects will receive a single injection of 1.0 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CNTX-4975 | Drug |
| ||
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline through Week 12 in average knee index pain with walking over previous 24 hours using WOMAC A1 question in subjects treated with CNTX-4975 1.0 mg compared to placebo in subjects with osteoarthritis (OA) of the knee | At 12 Weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline through Week 12 in average index knee pain with walking using WOMAC A1 question in subjects treated with CNTX 0.5 mg compared to placebo | At 12 Weeks | |
| Change from Baseline to each study visit through Week 24 in average index knee pain with walking using WOMAC A1 in subjects treated with CNTX-4975 compared to placebo |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Joint replacement surgery of the index knee at any time, or open surgery of the index knee in the past 12 months.
Prior arthroscopic surgery of the index knee within 3 months of Screening.
Any painful conditions of the index knee due to joint disease other than OA.
Mild pain in the non-index knee when walking.
Other chronic pain anywhere in the body that requires the use of analgesic medications.
Secondary OA of the index knee due to acute traumatic injury.
Significant current or past instability (e.g., cruciate ligament tear or rupture or previous repair) or misalignment (> 10 degrees varus or valgus) of the index knee
Has used topical capsaicin on the index knee within 90 days of Screening.
Corticosteroid injection in the index knee within 90 days of Screening.
Received IA viscosupplementation (e.g., Synvisc®, Hyalgan®) within 90 days of Screening.
Prior participation in an ALGRX 4975 or CNTX-4975 study.
Has any of the following characteristics:
Has moderate to severe depression or anxiety.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Achieve Clinical Research, LLC | Birmingham | Alabama | 35216 | United States | ||
| Advanced Arizona Clinical Research |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30888737 | Derived | Stevens RM, Ervin J, Nezzer J, Nieves Y, Guedes K, Burges R, Hanson PD, Campbell JN. Randomized, Double-Blind, Placebo-Controlled Trial of Intraarticular Trans-Capsaicin for Pain Associated With Osteoarthritis of the Knee. Arthritis Rheumatol. 2019 Sep;71(9):1524-1533. doi: 10.1002/art.40894. Epub 2019 Jul 17. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Up to 24 weeks |
| Change from Baseline through Week 4 in the average index knee pain with walking using the WOMAC A1 question | Up to 4 weeks |
| Tucson |
| Arizona |
| 85704 |
| United States |
| Dream Team Clinical Research, LLC | Anaheim | California | 92801 | United States |
| Hope Clinical Research, LLC | Canoga Park | California | 91303 | United States |
| TriWest Research Associates | El Cajon | California | 92020 | United States |
| BioSolutions Clinical Research Center | La Mesa | California | 91941 | United States |
| Axis Clinical Trials | Los Angeles | California | 90036 | United States |
| Avail Clinical Research, LLC | DeLand | Florida | 32720 | United States |
| Finlay Research Clinic | Hialeah | Florida | 33012 | United States |
| Eastern Research | Hialeah | Florida | 33013 | United States |
| Sunrise Medical Research | Lauderdale Lakes | Florida | 33319 | United States |
| M&M Medical Center, Inc | Miami | Florida | 85704 | United States |
| Compass Research, LLC | Orlando | Florida | 32806 | United States |
| Compass Research, LLC | The Villages | Florida | 32162 | United States |
| Clinical Research Atlanta | Stockbridge | Georgia | 30281 | United States |
| The Center for Pharmaceutical Research | Kansas City | Missouri | 64114 | United States |
| Drug Trials America | Hartsdale | New York | 10530 | United States |
| Manhattan Medical Research Practice | New York | New York | 10016 | United States |
| Wake Research Associates, LLC | Raleigh | North Carolina | 27612 | United States |
| University Orthopedics Center | Altoona | Pennsylvania | 16602 | United States |
| Altoona Center for Clinical Research | Duncansville | Pennsylvania | 16635 | United States |
| University Orthopedics Center | State College | Pennsylvania | 16801 | United States |
| ID | Term |
|---|---|
| D010003 | Osteoarthritis |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000656706 | CNTX-4975 |
Not provided
Not provided
Not provided